Search results
Showing 961 to 975 of 2580 results for methods
Evidence-based recommendations on rucaparib (Rubraca) for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy in adults.
What local anaesthetic techniques are most effective for women having surgical abortion?
abortion. The evidence that was available did not show that any particular method was more effective. The committee are aware that women...
Evidence-based recommendations on pembrolizumab (Keytruda) for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD L1 with a combined positive score (CPS) of 1 or more.
NICE has developed a medtech innovation briefing (MIB) on AlignRT in breast cancer radiotherapy .
In development Reference number: GID-HTE10068 Expected publication date: 06 January 2027
Software for electroencephalogram (EEG) interpretation to support diagnosing epilepsy
In development Reference number: GID-HTE10086 Expected publication date: 15 September 2026
Peripheral nerve-field stimulation for chronic low back pain (HTG309)
Evidence-based recommendations on peripheral nerve-field stimulation for chronic low back pain. This involves implanting electrodes in the back, connected to a neurostimulator under the skin to mask the back pain by modulating the transmission of pain signals to the brain.
View recommendations for HTG309Show all sections
Sections for HTG309
Risankizumab for treating moderately to severely active ulcerative colitis (TA998)
Evidence-based recommendations on risankizumab (Skyrizi) for treating moderately to severely active ulcerative colitis in adults.
A step-by-step summary about how we develop our technology appraisal guidance.
Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)
Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults.
In development Reference number: GID-HTE10072 Expected publication date: 19 November 2026
This guideline covers care before, during and after a planned knee, hip or shoulder replacement. It includes recommendations to ensure that people are given full information about their options for surgery, including anaesthesia. It offers advice for healthcare professionals on surgical procedures and ensuring safety during operations. It also offers guidance on providing support and rehabilitation before and after surgery.
Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease.
In development Reference number: GID-HTE10079 Expected publication date: 27 January 2027
Interventional procedures, IPG268 - Issued: July 2008 --> We have moved interventional procedures guidance 268 to become HealthTech guidance 171. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.